The regulation of hypoxia-inducible factor-1 (HIF-1) transcriptional activity in the nucleus is related to factor inhibiting HIF-1 (FIH-1). FIH-1 hydrolyzes asparagine at the C-terminal of HIF-1a, preventing the interaction between HIF-1a and its associated cofactors, and leading to suppressed activation of HIF-1. FIH-1 is a cytosolic protein and its entry to the nucleus has to be coordinated with HIF-1a. The present study was undertaken to examine the correlation between HIF-1a and FIH-1 in their nuclear entry. Human umbilical vein endothelial cells were treated with dimethyloxalylglycine at a final concentration of 100 mM for 4 h, resulting in an accumulation of HIF-1a and an increase of FIH-1 in the nucleus as determined by Western blot analysis. Pretreatment of the cells with copper (Cu) chelator tetraethylenepentamine at 50 mM in cultures for 24 h reduced both HIF-1a protein levels and the HIF-1a entry to the nucleus, along with decreased FIH-1 protein levels in the nucleus but no changes in the total FIH-1 protein levels in the cells. These effects were prevented by simultaneous addition of 50 mM CuSO 4 with tetraethylenepentamine. Gene-silencing of HIF-1a significantly inhibited FIH-1 entry to the nucleus, but did not affect the total protein levels of FIH-1 in the cells. This work demonstrates that the nuclear entry of FIH-1 depends on HIF-1a. Cu deficiency caused a decrease of HIF-1a, leading to suppression of FIH-1 entry to the nucleus.
Introduction
Factor inhibiting hypoxia-inducible factor-1 (FIH-1) 1 is found in both vertebrates and invertebrates extending from human, mouse, and rat to worm and fly. 2 FIH-1 has a 2-His-1-carboxylate facial triad of iron binding residues [3] [4] [5] [6] and is one of the 2-oxolutarate-dependent dioxygenases. [7] [8] [9] The dioxygenases require Fe 2þ , 2-oxoglutarate (2-OG), O 2 , and ascorbate for enzymatic activity. 1, 3 However, different dioxygenases hydroxylate distinguished residues of hypoxia-inducible factor-1a (HIF-1a). 10, 11 In brief, FIH-1 hydroxylates an asparagine residue of HIF-1a, 1, 12 whereas the other dioxygenases, proline hydroxylases (PHDs), hydroxylate the proline residues of HIF-1a. 13, 14 In addition, FIH-1 functions in the nucleus, regulating the formation of HIF-1 transcription complex, whereas PHDs function in the cytoplasm, 12 regulating the stability of HIF-1a. 14 Previous studies demonstrated that the transcription activity of HIF-1 requires copper (Cu): one possible mechanism is that Cu inhibits the activity of FIH-1, 15 protecting HIF-1a from the hydrolysis of asparagine at its C-terminal in the nucleus. The hydrolysis of asparagine prevents the interaction between HIF-1a and its associated cofactors, such as p300 and ARNT, leading to suppressed HIF-1a activation. [16] [17] [18] [19] Therefore, Cu inhibition of FIH-1 ensures the formation of HIF-1 transcription complex, leading to HIF-1 activation in the nucleus. 15 FIH-1 is mainly localized in cytoplasm; however, a small but significant portion of FIH-1 was also found in nucleus. 9 In particular, FIH-1 shuttles between cytoplasm and nucleus under hypoxia and reoxygenation condition. 20 But, it remains unclear how FIH-1 enters the nucleus and how its entry coordinates with the nuclear entry of HIF-1a. Therefore, the present study was undertaken to address the correlation between HIF-1 and FIH-1 in their entry to the nucleus, and the effect of Cu on this process.
Materials and methods

Cell culture and treatment
Human umbilical vein endothelial cells (HUVECs, American Type Culture Collection, Virginia, USA) were used because of their role in angiogenesis and the demonstrated function of HIF-1 in these cells. 21 Experimental procedures were described previously. 22 For varying treatments: cells were seeded in 6-well plates or T25 cell culture flasks, and grown overnight. Thereafter, dimethyloxalylglycine (DMOG, Sigma, St. Louis, USA), tetraethylenepentamine (TEPA, Sigma, St. Louis, USA) or CuSO 4 (Kelong, Chengdu, CN) were added to the cultures, followed by further incubation for a period of time as indicated in figure legends or the text of results section.
Nuclear and cytoplasmic extraction
The nucleus and cytoplasm were extracted using NE-PER Õ nuclear and cytoplasmic extraction reagents (Thermo Scientific, USA) according to the manufacturer's instruction.
Western blotting analysis of proteins
Protein extracts from nuclei, cytoplasm, and whole cells were prepared as described previously, 22 with some modifications. Briefly, 30 mg of protein from each sample was loaded onto a 10% SDS-polyacrylamide electrophoresis gel and transferred to a polyvinylidene difluoride membrane (Bio-RAD, USA). Blots were firstly probed with specific antibodies as follows: mouse anti-human HIF-1a monoclonal antibody (BD Biosciences, San Jose, USA), mouse anti-FIH-1 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, USA), goat anti-H2AX polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, USA), mouse anti-GAPDH monoclonal antibody (ZSGB-BIO, Beijing, CN) and mouse anti-beta Actin monoclonal antibody (ZSGB-BIO, Beijing, CN). Then the membranes were incubated with a horseradish peroxidase-linked antimouse or anti-rabbit IgG antibody (ZSGB-BIO, Beijing, CN), and protein bands were visualized as described previously 22 and analyzed by densitometry using Quantityone 1-D analysis software.
Real-time quantitative RT-PCR
RNA extraction and quantification were performed according to the protocol reported previously. 22 The primer sequences were designed as shown below:
Gene name
Gene sequence
Gene silencing of HIF-1a
The siRNA targeting human HIF-1a and mismatched control were designed and synthesized from RiboBio (Guangzhou, China). The siRNA sequences for HIF-1a were as follows: sense, GGCCUCUGUGAUGAGGCUUtt; antisense, AAGCCUCACAGAGGCCtt. Mismatched control siRNA sequences were as follows: sense, UUCUC CGAACGUACGUtt; antisense, ACGUGACACG UUCGGAGAAtt. The optimal transfection efficiency was determined from our preliminary study testing 50 nM or 100 nM, and we selected the condition that the siRNA caused an optimal silencing effect with minimal cytotoxicity. After HUVECs were transfected with 50 nM annealed siRNA targeting human HIF-1a or negative mismatched control siRNA in serum-or antibiotics-free media, a Lipofectamine 2000 reagent (Invitrogen, California, USA) was used as the transfection reagent according to the manufacturer's instruction.
Statistical analysis
Data were obtained from three separate experiments and presented as mean values AE SEM. The significance of differences was determined by one-way ANOVA and further analyzed by Dunnett's T3 test for comparison among multiple groups. The level of significance was considered at P < 0.05.
Results
The nuclear purity was qualified using the nucleus specific marker histone 2AX and the cytoplasm specific marker GAPDH (Figure 1(a) ). Histone 2AX was detected in the nuclear fraction, but not in the cytoplasm, and conversely, GAPDH was only found in the cytoplasm. Treatment of HUVECs with DMOG at a final concentration of 100 mM for 4 h significantly increased FIH-1 protein levels in the nucleus, as shown in Figure 1(b) . When the cells were pretreated with 50 mM TEPA (final concentration in cultures) for 20 h, and then exposed to DMOG for 4 h, the nuclear FIH-1 protein levels were reduced. This reduction was prevented by a simultaneous addition of 50 mM CuSO 4 with TEPA. In contrast, DMOG treatment decreased the protein levels of FIH-1 in the cytoplasm (Figure 1(c) ); opposite to the increase in the nucleus (Figure 1(b) ). TEPA pretreatment prevented the decrease in FIH-1 protein levels in the cytoplasm, and the TEPA effect was reversed by the addition of CuSO 4 with TEPA simultaneously. Unlike the changes in the nuclear and cytoplasmic levels of FIH-1, the total protein levels of FIH-1 were not altered under different treatment conditions (Figure 1(d) ).
Under the same condition noted above, HIF-1a protein levels in the nucleus were increased after 4-h treatment with DMOG, and this increase was prevented by pretreatment with TEPA, which was preventable by a simultaneous addition of CuSO 4 with TEPA (Figure 2(a) ). The protein levels of HIF-1a in the cytoplasm were barely detectable under all the conditions (Figure 2(b) ), but the changes in the total HIF-1a protein levels followed the same pattern as observed for the nuclear fraction (Figure 2(c) ).
Gene silencing of HIF-1a resulted in a significant decrease in both protein and mRNA levels of HIF-1a ( Figure 3 ), along with a significant decrease in the nuclear level of FIH-1 proteins (Figure 4(a) ), but no significant changes in the total protein levels of FIH-1 in the cells (Figure 4(b) ).
Discussion
FIH-1 is a protein encoded by the Hif1an gene and found in the cytoplasm. 1 One of its functions is to hydrolyze asparagine at the C-terminal of HIF-1a in the nucleus. 12, 16 This raises a question: how is the nuclear entry of FIH-1 regulated? Since the function of FIH-1 is coupled to the nuclear location of HIF-1a, it is reasonable to speculate that the nuclear entry between HIF-1a and FIH-1 is coordinated. On the other hand, Cu also enters the nucleus and functions in the regulation of HIF-1 transcriptional activity through at least in part the inhibition of FIH-1 activity. 15 Therefore, we made an attempt here to examine the correlation between HIf-1a and FIH-1 in their entry to the nucleus and the effect of Cu on this process.
The measurement of cytoplasmic versus nuclear levels of FIH-1 protein through isolation of nuclear fraction was effective as demonstrated by the purity test of the nuclear marker histone-2AX and the cytoplasm marker GAPDH in the isolated fractions. DMOG inhibits the PHDs leading to HIF-1a accumulation in the cells. 10, 23 Under this DMOG treatment condition, the level of nucleus FIH-1 was significantly increased and the pretreatment with Cu chelator TEPA prevented this increase. The TEPA effect was due to Cu deficiency, as evidenced by the antagonistic effect of simultaneous addition of equal molar Cu with TEPA. Under these treatment conditions, the total protein levels of FIH-1 were not changed, as further evidenced by the increased nuclear levels along with decreased cytoplasm levels of FIH-1, and vice versa. These together suggest that Cu is related to the nuclear entry of FIH-1 but does not affect the turnover of the FIH-1 proteins. Gene silencing using siRNA targeting HIF-1a effectively depressed total and nuclear levels of HIF-1a proteins. Under this condition, Cu levels in the cells would not be affected. But, we observed that with the depletion of HIF-1a, DMOG-induced nuclear entry of FIH-1 was completely depressed. Therefore, it suggests that the accumulation of HIF-1a and its nuclear translocation most likely trigger the nuclear entry of FIH-1.
One of the limitations of this study is that we do not understand how Cu deficiency reduces the protein levels of HIF-1a induced by DMOG. We previously observed that TEPA treatment after HIF-1a accumulation induced by hypoxia 15 or cobalt chloride 22 does not affect the total protein levels of HIF-1a. But this study here demonstrates that Cu deficiency prior to DMOG treatment prevents the increase of HIF-1a in the cells, suggesting an inhibition of HIF-1a synthesis by Cu deficiency may take place, which needs to be investigated in the future.
In summary, the present study demonstrates that FIH-1 nuclear entry is dependent on HIF-1a accumulation and nuclear entry, and Cu deficiency prevents FIH-1 nuclear entry through suppression of total protein levels of HIF-1a.
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